Clinical endpoints in allogeneic hematopoietic stem cell transplantation studies: The cost of freedom

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 6, 2013, Pages 860-866

  Kim, Haesook T ^a   Armand, Philippe ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Allogeneic transplantation; Clinical endpoints; Competing risks data

Indexed keywords

16,16 DIMETHYLPROSTAGLANDIN E2;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; CONSENSUS; CORD BLOOD STEM CELL TRANSPLANTATION; GRAFT FAILURE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEALTH SURVEY; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; MORTALITY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; RELAPSE; REVIEW; RISK ASSESSMENT;

ENDPOINT DETERMINATION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIVARIATE ANALYSIS; RECURRENCE; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84877927809     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.01.003     Document Type: Review

References (31)

1. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.
2. Clift R.A., Buckner C.D., Appelbaum F.R., et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990, 76:1867-1871.
3. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997, 89:4531-4536.
4. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91:756-763.
5. Niederwieser D., Maris M., Shizuru J.A., et al. Low-dose total body irradiation (TBI) and fl{ligature}udarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003, 101:1620-1629.
6. Fine J.P., Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
7. Klein J.P., Andersen P.K. Regression modeling of competing risks data based on pseudovalues of the cumulative incidence function. Biometrics 2005, 61:223-229.
8. Cox D.R., Oakes D. Analysis of survival data 1984, Chapman and Hall, London, p. 91-110.
9. Davies S.M., Kollman C., Anasetti C., et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood 2000, 96:4096-4102.
10. Brunstein C.G., Gutman J.A., Weisdorf D.J., et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010, 116:4693-4699.
11. Ramírez P., Brunstein C.G., Miller B., et al. Delayed platelet recovery after allogeneic transplantation: a predictor of increased treatment-related mortality and poorer survival. Bone Marrow Transplant 2011, 46:981-986.
12. Wagner J.E., Barker J.N., DeFor T.E., et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002, 100:1611-1618.
13. Gluckman E., Rocha V., Arcese W., et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol 2004, 32:397-407.
14. Terakura S., Azuma E., Murata M., et al. Hematopoietic engraftment in recipients of unrelated donor umbilical cord blood is affected by the CD34+ and CD8+ cell doses. Biol Blood Marrow Transplant 2007, 13:822-830.
15. Kalbfleisch J.D., Prentice R.L. The statistical analysis of failure time data 2002, John Wiley & Sons, New York.
16. Gray R.J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16:1140-1154.
17. Kim H.T. Cumulative incidence in a competing risks setting and competing risks regression analysis. Clin Cancer Res 2007, 13:559-565.
18. 2)-enhanced umbilical cord blood accelerates hematopoietic engraftment after reduced intensity conditioning and double umbilical cord blood transplantation. Blood (ASH Annual Meeting Abstracts) 2011, 118:653.
19. Eapen M., Rocha V., Sanz G., et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010, 11:653-660. Center for International Blood and Marrow Transplant Research; Acute Leukemia Working Party Eurocord (the European Group for Blood Marrow Transplantation); National Cord Blood Program of the New York Blood Center.
20. Aversa F., Tabilio A., Velardi A., et al. Treatment of high-risk acute leukemia with T-cell depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998, 339:1186-1193.
21. Marmont A.M., Horowitz M.M., Gale R.P., et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991, 78:2120-2130.
22. Ringdén O., Pavletic S.Z., Anasetti C., et al. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood 2009, 113:3110-3118.
23. Baron F., Maris M.B., Sandmaier B.M., et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005, 23:1993-2003.
24. Gupta V., Tallman M.S., He W., et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood 2010, 116:1839-1848.
25. Arora M., Klein J.P., Weisdorf D.J., et al. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood 2011, 117:6714-6720. [Erratum in: Blood 2011 Dec 22;118(26):6992.].
26. Logan B.R., Zhang M.J., Klein J.P. Regression models for hazard rates versus cumulative incidence probabilities in hematopoietic cell transplantation data. Biol Blood Marrow Transplant 2006, 12(1 suppl 1):107-112.
27. Klein J.P. Modelling competing risks in cancer studies. Stat Med 2006, 25:1015-1034.
28. Andersen P.K., Abildstrom S.Z., Rosthøj S. Competing risks as a multi-state model. Stat Methods Med Res 2002, 11:203-215.
29. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
30. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
31. Martin P.J., Weisdorf D., Przepiorka D., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant 2006, 12:491-505.